淋巴细胞抗原6复合物E的表达与POF方案治疗晚期胃癌疗效的相关性分析

目的:探讨晚期胃癌患者中淋巴细胞抗原6复合物E(LY6E)的表达与“紫杉醇脂质体+奥沙利铂+氟尿嘧啶”（POF）方案化疗疗效的关系。方法:收集45例一线接受POF化疗的晚期胃癌患者的临床、病理资料，采用免疫组化法检测其LY6E的表达情况，计算客观有效率(ORR)和疾病控制率(DCR)，统计分析LY6E的表达与胃癌患者临床病理特征、近期疗效及临床受益率的关系。结果:45例患者中，LY6E的阳性率为71.1%。未分化－低分化腺癌LY6E的阳性表达率显著高于中－高分化腺癌(78.9% vs 28.6%，P<0.05)。45例患者ORR为31.1%，DCR为55.6%，临床受益率为40.0%。与LY6E(－)患者相比，LY6E(＋)患者的ORR、DCR和临床受益率均显著降低（ORR:18.8% vs 61.5%；DCR:43.8% vs 84.6%；临床受益率:28.1% vs 69.2%）（P<0.05）。LY6E的表达与POF方案所致化疗毒副反应无显著相关性(P>0.05)。结论:LY6E与晚期胃癌分化程度相关，晚期胃癌患者中LY6E的表达可能成为预测POF方案化疗敏感性的新指标，并有可能成为胃癌治疗潜在的新靶点。

Correlative analysis of the expression of LY6E with the efficacy of POF regimen for advanced gastric cancer

Objective:To investigate the correlation of lymphocyte antigen 6 complex，locus E (LY6E) expression with the efficacy of "taxol liposome+oxaliplatin+fluorouracil"（POF） for advanced gastric cancer.Methods:45 patients with advanced gastric cancer who were treated with POF as first line therapy were enrolled in the present study，and the clinical data and pathological samples were collected.The expression of LY6E was detected by immunohistochemical staining.The objective response rate (ORR) and disease control rate (DCR) were calculated.The relationship of LY6E expression with clinical data，therapeutic efficacy，clinical benefit response were analyzed.Results:The positive rate of LY6E in the total 45 patients was 71.1%，and the positive rate in undifferentiated or poorly differentiated patients was significantly higher than moderately or well differentiated patients (78.9% vs 28.6%，P<0.05).Total ORR，DCR and the clinical benefit response rate were 31.1%，55.6% and 40.0%，respectively.ORR，DCR and the clinical benefit response rate of patients with positive LY6E were significantly lower than the patients with negative LY6E expression (ORR:18.8% vs 61.5%，DCR:43.8% vs 84.6%，clinical benefit response rate:28.1% vs 69.2%，P<0.05).No significant correlation was detected between LY6E expression and the incidence of POF regimen induced adverse reactions(P>0.05).Conclusion:LY6E is related to the histology grade of advanced gastric cancer.Patients with negative LY6E might get more benefit from POF therapy，and LY6E might become a new novel predictor of the therapeutic efficacy，prognosis and a potential therapeutic target of advanced gastric cancer.